SUBSCRIBE: Print / eNewsletter
Depressive symptoms and impaired executive functioning, both common in patients with glioblastoma, are independently associated with shorter overall survival.
A core set of symptoms are common across brain tumor patients and underscore the complexity of brain tumors and their management.
New research suggests that characterizing low-grade gliomas according to molecular markers may be a more useful approach in order to guide treatment decisions.
The immunotherapeutic rindopepimut with bevacizumab yielded a significant survival improvement in relapsed glioblastoma patients with a EGFRvIII mutation.
A phase I trial of an oncolytic polio/rhinovirus vaccine was safe and showed promising efficacy in patients with recurrent glioblastoma.
Treating newly diagnosed glioblastoma with “tumor treating fields” is a safe and effective therapeutic option, according to a new trial.
The addition of procarbazine, CCNU, and vincristine to RT in patients with low-grade glioma prolongs progression-free and overall survival vs RT alone.
A combination of bevacizumab and lomustine showed promise in a randomized phase II trial of patients with recurrent glioblastoma, according to study results.
As part of our Society of Neuro-Oncology annual meeting coverage, we discuss quality of life issues and neurologic rehabilitation in patients with neuro-oncologic diseases.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
